

OTREXUP PFS - (10MG/0.4ML, 15MG/0.6ML, 17.5MG/0.7ML, 20MG/0.8ML, 22.5MG/0.9ML, 25MG/1ML)

Generic Name	METHOTREXATE	Innovator	None
Dosage	10MG/0.4ML, 15MG/0.6ML, 17.5MG/0.7ML, 20MG/0.8ML, 22.5MG/0.9ML, 25MG/1ML	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Otrexup PFS is a folate analog metabolic inhibitor indicated for the: • Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy. • Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.